Syphilis Serology Interpreter
Syphilis Serology Interpreter
Read a treponemal and a non-treponemal result together — including the prozone trap, the discordant reverse-sequence result and the fourfold titre change.
Syphilis serology
Two tests + titre → interpretationTreponemal EIA reactive, RPR reactive at 1:32, no previous titre, no documented previous treatment, a painless genital ulcer present
Reading the two tests together
- Treponemal
- reactive for life in most people after infection, treated or not — so it cannot stage or monitor
- Non-treponemal
- quantitative; the titre tracks activity and treatment response
- Traditional algorithm
- non-treponemal test first, reactive samples confirmed with a treponemal test
- Reverse sequence
- automated treponemal immunoassay first, then a quantitative non-treponemal test; discordant results adjudicated by a second treponemal assay of a different format
- Fourfold change
- two dilutions on the same assay — the smallest change CDC treats as clinically significant
- Prozone
- antibody excess blocking the undiluted non-treponemal reaction, producing a false negative that only dilution reveals
Worked example
Treponemal EIA reactive, RPR reactive at 1:32, no previous titre, no documented previous treatment, a painless genital ulcer present
Treponemal test reactive and RPR reactive → a genuine treponemal antibody response, not a false positive
No documented previous treatment, so past treated infection does not explain it
Compatible clinical signs present → active syphilis
1:32 becomes the baseline titre; an adequate response is a fourfold fall, to 1:8 or lower, on the same assay
What each combination means
| Treponemal | Non-treponemal | Usual interpretation |
|---|---|---|
| Reactive | Reactive | Syphilis — untreated, inadequately treated, recently treated, or serofast after treatment. Titre and history separate them |
| Reactive | Non-reactive | Discordant. Needs a second treponemal assay of a different format. If signs are present, also exclude a prozone by dilution |
| Non-reactive | Reactive | Probable biological false positive (0.2–0.8% of the population). Confirm with a second treponemal assay |
| Non-reactive | Non-reactive | No serological evidence of syphilis — but neither test may yet be reactive in very early primary infection |
The two algorithms
| Traditional | Reverse sequence | |
|---|---|---|
| Screens with | RPR or VDRL | Automated treponemal EIA or CIA |
| Then does | A treponemal test on reactive samples | A quantitative non-treponemal test on reactive samples |
| Misses | Early primary and late latent infection, where the non-treponemal test can be non-reactive | Very little — the treponemal test is the more sensitive screen |
| Produces | Fewer discordant results | The characteristic treponemal-reactive, non-treponemal-non-reactive discordance |
| Discordance resolved by | A second treponemal assay of a different format | A second treponemal assay of a different format, preferably TPPA |
Titres and dilutions
| Change in titre | Dilutions | Meaning |
|---|---|---|
| 1:32 → 1:8 | Two, downward | Fourfold fall — adequate serological response |
| 1:8 → 1:32 | Two, upward | Fourfold rise — treatment failure, relapse or reinfection |
| 1:32 → 1:16 | One | Not a clinically significant change |
| 1:4 or lower, stable, after treatment | — | Serofast state; typically ≤1:8 |
The prozone phenomenon, and why a negative RPR can mean a very high titre
Syphilis serology needs two tests because neither answers the whole question. A treponemal test — TPPA, TPHA, or an automated EIA or CIA — detects antibody to Treponema pallidum itself and answers “has this person ever had syphilis”. A non-treponemal test — RPR or VDRL — detects antibody to lipoidal antigens released by damaged cells, is quantitative, and answers “is it active, and how active”. CDC is explicit that “use of only one type of serologic test (nontreponemal or treponemal) is insufficient for diagnosis and can result in false-negative results among persons tested during primary syphilis”.
The single most important limitation is that the treponemal test does not clear. “The majority of patients who have reactive treponemal tests will have reactive tests for the remainder of their lives, regardless of adequate treatment or disease activity.” So a reactive TPPA fifteen years after a fully treated primary infection looks identical to a reactive TPPA in untreated latent disease. Nothing in the treponemal result distinguishes them; only the non-treponemal titre, the treatment record and the clinical picture can. This is also why a titre is worth chasing from the laboratory rather than accepting a bare “RPR reactive” — without a number there is nothing to follow.
The trap most worth knowing is the prozone phenomenon. In secondary syphilis the non-treponemal antibody concentration can be so high that it saturates the reaction and blocks agglutination, so the undiluted sample reads non-reactive while the same sample diluted reads strongly positive. The direction of the error is counter-intuitive — the falsely negative result is caused by too much antibody, not too little — and it lands on exactly the patients who are most infectious. CDC’s 2024 laboratory recommendations put the overall frequency at under 0.85% across two series of 4,328 and 46,856 patients, but at 4.7% in primary and 1.8% in secondary syphilis, and note that of 36 affected samples two only became reactive at dilutions of 1:256 and 1:512. Laboratories are advised not to dilute every non-reactive sample as a matter of routine, but to “rule out a prozone using a dilution series… when requested by a clinician” — which means that in a patient with a rash or a chancre and a reactive treponemal test, asking for the dilution is your job, not the laboratory’s.
Two further rules make the rest of the page work. First, the reverse-sequence algorithm — automated treponemal immunoassay first — generates a discordant result the traditional algorithm rarely did: treponemal reactive, non-treponemal non-reactive. That combination is not interpretable on its own and CDC requires it to be “adjudicated by a second treponemal assay (e.g., TPPA) that has a different format”. Second, change is measured in fourfolds. “A fourfold change in titer, equivalent to a change of two dilutions… is considered necessary for demonstrating a clinically significant difference between two nontreponemal test results” — a fall of four or more indicates response, a rise of four or more indicates failure, relapse or reinfection, and a single dilution either way is noise. That comparison only holds if both results came from the same assay, ideally the same laboratory, because RPR and VDRL are read by eye and are not interchangeable. This supports a clinician’s judgement rather than replacing it. It is arithmetic on the figures entered, and it knows nothing about the patient in front of you.
Frequently asked questions
What is the prozone phenomenon?
Antibody in such excess that it blocks the agglutination reaction the RPR or VDRL depends on, so the undiluted sample reads non-reactive while a diluted sample reads strongly positive. It is most common in primary and secondary syphilis, and the laboratory has to be asked to run a dilution series — CDC advises against diluting every non-reactive sample routinely.
Why can a treponemal test not tell treated from untreated syphilis?
Because it stays reactive. CDC: “the majority of patients who have reactive treponemal tests will have reactive tests for the remainder of their lives, regardless of adequate treatment or disease activity”. Activity and response are judged on the quantitative non-treponemal titre instead.
What does a treponemal-reactive, non-treponemal-non-reactive result mean?
It is the characteristic discordant result of the reverse-sequence algorithm and is not interpretable on its own. It requires a second treponemal assay of a different format, preferably TPPA. If the patient has signs of syphilis, a prozone should be excluded by dilution at the same time.
How much titre change is meaningful?
Fourfold — two dilutions. A fall of four or more indicates an adequate serological response; a rise of four or more indicates treatment failure, relapse or reinfection. One dilution is within the assay’s own variation. The comparison is only valid between results from the same test type.
What is the serofast state?
A non-treponemal titre that stays reactive after adequate treatment instead of reverting to non-reactive. CDC describes it as commonest in people treated a year or more after acquiring syphilis or with repeated episodes, with titres “typically ≤1:8, but higher titers also have been observed”. Calling a result serofast requires a previous titre to show it is stable.
Related calculators
References
- Papp JR, Park IU, Fakile Y, Pereira L, Pillay A, Bolan GA. CDC laboratory recommendations for syphilis testing, United States, 2024. MMWR Recomm Rep. 2024;73(1):1–32.
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.
- Liu LL, Lin LR, Tong ML, et al. Incidence and risk factors for the prozone phenomenon in serologic testing for syphilis in a large cohort. Clin Infect Dis. 2014 (PMID 24803377).
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.